Q1 Earnings Estimate for ATRA Issued By HC Wainwright

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Atara Biotherapeutics in a report released on Tuesday, August 19th. HC Wainwright analyst R. Burns anticipates that the biotechnology company will earn $2.46 per share for the quarter. The consensus estimate for Atara Biotherapeutics’ current full-year earnings is ($10.39) per share. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.52) EPS and Q4 2026 earnings at ($0.49) EPS.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Monday, August 11th. The biotechnology company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.51. Atara Biotherapeutics had a net margin of 3.07% and a negative return on equity of 8.34%. The company had revenue of $17.58 million for the quarter, compared to analyst estimates of $4.23 million.

Atara Biotherapeutics Price Performance

ATRA opened at $11.76 on Wednesday. Atara Biotherapeutics has a fifty-two week low of $5.01 and a fifty-two week high of $18.70. The firm has a market capitalization of $82.56 million, a PE ratio of -27.35 and a beta of 0.26. The company’s 50-day moving average is $9.98 and its 200 day moving average is $8.19.

Insider Buying and Selling at Atara Biotherapeutics

In other Atara Biotherapeutics news, major shareholder Innovation Ltd Panacea bought 55,000 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were bought at an average price of $12.19 per share, for a total transaction of $670,450.00. Following the acquisition, the insider directly owned 1,405,000 shares of the company’s stock, valued at approximately $17,126,950. The trade was a 4.07% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new stake in shares of Atara Biotherapeutics in the 2nd quarter worth about $31,000. Marshall Wace LLP bought a new stake in Atara Biotherapeutics in the 2nd quarter worth about $327,000. Geode Capital Management LLC grew its position in Atara Biotherapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock worth $464,000 after purchasing an additional 1,457 shares in the last quarter. EcoR1 Capital LLC grew its position in Atara Biotherapeutics by 7.7% in the 1st quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company’s stock worth $3,405,000 after purchasing an additional 41,049 shares in the last quarter. Finally, Staley Capital Advisers Inc. grew its position in Atara Biotherapeutics by 60.0% in the 1st quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company’s stock worth $475,000 after purchasing an additional 30,000 shares in the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.